- Trials with a EudraCT protocol (96)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
96 result(s) found for: Nivolumab and NSCLC.
Displaying page 2 of 5.
EudraCT Number: 2019-002986-36 | Sponsor Protocol Number: NIBIT-ML-1 | Start Date*: 2020-06-19 | |||||||||||
Sponsor Name:FONDAZIONE NIBIT NETWORK ITALIANO PER LA BIOTERAPIA DEI TUMORI | |||||||||||||
Full Title: A randomized, run-in, phase II study of nivolumab combined with ipilimumab and guadecitabine or nivolumab combined with ipilimumab in melanoma and NSCLC patients resistant to anti-PD-1/PD-L1 | |||||||||||||
Medical condition: MM and NSCLC patients resistant to anti-PD-1/PD-L1 therapy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-005741-31 | Sponsor Protocol Number: AIO-YMO/TRK-0415 | Start Date*: 2016-12-02 | ||||||||||||||||
Sponsor Name:AIO-Studien-gGmbH | ||||||||||||||||||
Full Title: Fostering efficacy of anti – PD-1 – treatment: Nivolumab plus radiotherapy in advanced NSCLC | ||||||||||||||||||
Medical condition: metastatic non-squamous Non-Small Cell Lung Cancer (Lung adenocarcinoma metastatic and Large cell lung cancer metastatic) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-003731-37 | Sponsor Protocol Number: CA209-907 | Start Date*: 2017-10-18 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: An Open-label, single-arm Phase II Safety Study of Nivolumab in Subjects with Advanced or metastatic non-small cell lung cancer who have progressed during or after receiving at least one prior syst... | |||||||||||||
Medical condition: Advanced or metastatic non-small cell lung cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: RO (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-000137-17 | Sponsor Protocol Number: BA3021-001 | Start Date*: 2022-09-27 | ||||||||||||||||
Sponsor Name:BioAtla | ||||||||||||||||||
Full Title: A Phase 1/2 Dose Escalation and Dose Expansion Study of Ozuriftamab Vedotin (BA3021) Alone and in Combination with Nivolumab in Patients with Advanced Solid Tumors | ||||||||||||||||||
Medical condition: Advanced solid tumors | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Completed) GR (Completed) IT (Prematurely Ended) DE (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002423-29 | Sponsor Protocol Number: INCB24360-204 | Start Date*: 2017-07-13 |
Sponsor Name:incyte Corporation | ||
Full Title: A Phase 1/2 Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers | ||
Medical condition: Selected advanced cancers, including metastatic and/or unresectable solid tumors including NSCLC, melanoma,adenocarcinoma of the colon or rectum , recurrent squamous cell carcinoma of the head and ... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-002478-29 | Sponsor Protocol Number: CA224-063 | Start Date*: 2019-11-27 | |||||||||||
Sponsor Name:University Hospital Essen | |||||||||||||
Full Title: Neoadjuvant nivolumab combination treatment in resectable non-small cell lung cancer patients: Defining optimal combinations and determinants of immunological response (NEOpredict-Lung) | |||||||||||||
Medical condition: non-small cell lung cancer (NSCLC) of clinical stages IB, II and selected stage III A | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) BE (Trial now transitioned) NL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-003731-20 | Sponsor Protocol Number: CEGF816X2201C | Start Date*: 2015-05-19 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A phase II, multicenter, open-label study of EGF816 in combination with Nivolumab in adult patients with EGFR mutated non-small cell lung cancer and of INC280 in combination with Nivolumab in adult... | |||||||||||||
Medical condition: EGFR mutated non-small cell lung cancer and EGFR wild-type non-small cell lung cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) ES (Completed) NL (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000958-98 | Sponsor Protocol Number: 2017-1-39-007 | Start Date*: 2020-08-07 | |||||||||||
Sponsor Name:Centre Régional de lutte contre le Cancer Eugène Marquis | |||||||||||||
Full Title: A phase II trial evaluating conformational intensity modulated radiotherapy with concomitant nivolumab followeb by nivolumab for patients with locally advanced non-small cell lung cancer | |||||||||||||
Medical condition: Patient having locally Advanced Non-Small Cell Lung Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-003334-25 | Sponsor Protocol Number: Uni-Koeln-2785 | Start Date*: 2017-01-26 | |||||||||||||||||||||||||||||||||||||||||
Sponsor Name:University of Cologne | |||||||||||||||||||||||||||||||||||||||||||
Full Title: A phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in relapsed lung cancer and to evaluate biomarkers predictive for response to immune checkpoint inhibition | |||||||||||||||||||||||||||||||||||||||||||
Medical condition: Patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) and patients with Small cell lung cancer (SCLC) after failure of platinum-based first-line therapy. | |||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||
Trial protocol: DE (Completed) | |||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-001043-41 | Sponsor Protocol Number: 516-005 | Start Date*: 2020-11-03 | |||||||||||
Sponsor Name:Mirati Therapeutics, Inc. | |||||||||||||
Full Title: A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Plat... | |||||||||||||
Medical condition: Non-Squamous Non-Small Cell Lung Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) BE (Completed) HU (Completed) NL (Trial now transitioned) GB (GB - no longer in EU/EEA) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-004502-93 | Sponsor Protocol Number: CA209-026 | Start Date*: 2014-04-23 | ||||||||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | ||||||||||||||||||
Full Title: An Open-Label, Randomized, Phase 3 Trial of Nivolumab versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer | ||||||||||||||||||
Medical condition: Stage IV or Recurrent Non-Small Cell Lung Cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Ongoing) DE (Completed) BE (Completed) AT (Completed) GB (GB - no longer in EU/EEA) SE (Completed) FI (Completed) CZ (Completed) HU (Completed) IT (Completed) FR (Completed) NL (Completed) RO (Ongoing) PL (Completed) GR (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-005187-34 | Sponsor Protocol Number: CCR4644 | Start Date*: 2017-09-11 |
Sponsor Name:The Royal Marsden NHS Foundation Trust | ||
Full Title: Stereotactic body radiotherapy with immunotherapy in early stage non-small cell lung cancer: tolerability and lung effects | ||
Medical condition: Non small-cell lung cancer (NSCLC) Stage: T1-3( ≤5cm)N0M0) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2012-002472-14 | Sponsor Protocol Number: CA209-057 | Start Date*: 2012-12-20 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: An Open-Label Randomized Phase III Trial of BMS-936558 (Nivolumab) versus Docetaxel in Previously Treated Metastatic Non-squamous Non-small cell Lung Cancer (NSCLC) | |||||||||||||
Medical condition: Non-Squamous cell Non-small cell lung cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) AT (Completed) ES (Ongoing) HU (Completed) CZ (Completed) IT (Completed) PL (Completed) NO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-003304-43 | Sponsor Protocol Number: INCB24360-309 | Start Date*: 2018-04-12 | ||||||||||||||||
Sponsor Name:Incyte Corporation | ||||||||||||||||||
Full Title: A Phase 3, Randomized, Global Trial of Nivolumab and Epacadostat with Platinum Doublet Chemotherapy versus Platinum Doublet Chemotherapy in First-line Treatment of Stage IV or Recurrent Non-Small C... | ||||||||||||||||||
Medical condition: Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-000367-33 | Sponsor Protocol Number: CA209-9GW | Start Date*: 2017-08-07 | |||||||||||||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||||||||||||
Full Title: Phase 1/2 Study to Evaluate the Safety and Preliminary Efficacy of Nivolumab Combined with Daratumumab in Participants with Advanced or Metastatic Solid Tumors | |||||||||||||||||||||||
Medical condition: Advanced or metastatic solid tumors | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Completed) ES (Completed) FR (Completed) IT (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2022-000135-23 | Sponsor Protocol Number: BA3011-002 | Start Date*: 2023-02-13 | |||||||||||
Sponsor Name:BioAtla Inc. | |||||||||||||
Full Title: A Phase 2 Study of Mecbotamab Vedotin (BA3011) Alone and in Combination with Nivolumab in Adult Patients with Metastatic Non-Small Cell Lung Cancer Who Had Prior Disease Progression On or Are Intol... | |||||||||||||
Medical condition: Metastatic Non-Small Cell Lung Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001585-42 | Sponsor Protocol Number: CA209-8KX | Start Date*: 2019-01-09 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | ||||||||||||||||||||||||||||||||||||||
Full Title: Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy | ||||||||||||||||||||||||||||||||||||||
Medical condition: The study population will include participants with 1 of the following advanced or metastatic tumors approved for treatment with nivolumab monotherapy: non-small cell lung cancer (NSCLC); renal ce... | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: PL (Ongoing) GB (GB - no longer in EU/EEA) ES (Ongoing) NL (Trial now transitioned) IT (Trial now transitioned) | ||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001743-12 | Sponsor Protocol Number: INCB24360-208 | Start Date*: 2018-07-04 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Incyte Corporation | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: A Phase 1/2, Open-Label, Dose-Escalation, Safety, Tolerability, and Efficacy Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Subjects With Advanced or Metastatic Maligna... | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Phase 1 (Dose Escalation): Advanced or metastatic solid tumors. Phase 2 (Dose Expansion): Advanced or metastatic non–small cell lung cancer (NSCLC), unresectable or metastatic melanoma (MEL) and r... | |||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-005115-41 | Sponsor Protocol Number: TG4010.24 | Start Date*: 2017-11-29 | |||||||||||
Sponsor Name:Transgene S.A. | |||||||||||||
Full Title: A phase II study evaluating the efficacy and the safety of first-line chemotherapy combined with TG4010 and nivolumab in patients with advanced non-squamous Non-Small-Cell Lung Cancer (NSCLC) | |||||||||||||
Medical condition: Stage IIIB-IV non small cell lung cancer (NSCLC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) HU (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000340-26 | Sponsor Protocol Number: CA027-002 | Start Date*: 2018-10-31 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers | |||||||||||||
Medical condition: Advanced Cancers | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) GB (GB - no longer in EU/EEA) BE (Trial now transitioned) DE (Trial now transitioned) IT (Trial now transitioned) PL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
